| [1] |
Bertuccio P, Turati F, Carioli G, et al. Global trends and predictions in hepatocellular carcinoma mortality. J Hepatol, 2017,67:302-309.
|
| [2] |
Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol, 2017,3:1683-1691.
|
| [3] |
Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva: World Health Organization, 2015.
|
| [4] |
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology, 2011,53:1020-1022.
|
| [5] |
Johnson P J, Pirrie S J, Cox T F, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiology Biomarkers & Prevention, 2014,23:144-153.
|
| [6] |
Barletta E, Tinessa V, Daniele B. Screening of hepatocellular carcinoma: role of the alpha-fetoprotein (AFP) and ultrasonography . Recenti Prog Med, 2005,96:295-299, 328.
|
| [7] |
Marrero J A. Screening tests for hepatocellular carcinoma. Clin Liver Dis, 2005,9:235-251.
|
| [8] |
中华人民共和国国家卫生和计划生育委员会,原发性肝癌诊疗规范2017年版.临床肝胆病杂志,2017,33:1419-1431.
|
| [9] |
Yi X, Yu S, Bao Y. Alpha-fetoprotein-L3 in hepatocellular carcinoma: a meta-analysis. Clin Chim Acta, 2013,425:212-220.
|
| [10] |
Jia Z, Wang L, Liu C, et al. Evaluation of alpha-fetoprotein-L3 and Golgi protein 73 detection in diagnosis of hepatocellular carcinoma. Contemp Oncol (Pozn), 2014,18:192-196.
|
| [11] |
Durazo F A, Blatt L M, Corey W G, et al. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol, 2008,23:1541-1548.
|
| [12] |
Volk M L, Hernandez J C, Su G L, et al. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark, 2007,3:79-87.
|
| [13] |
Lim T S, Kim D Y, Han K H, et al. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients. Scand J Gastroenterol, 2016,51:344-353.
|
| [14] |
Berhane S, Toyoda H, Tada T, et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin Gastroenterol Hepatol, 2016,14:875-886.
|
| [15] |
林清标,董菁,柯坤宇等,GALAD模型在肝细胞癌患者中的诊断价值验证.中华肝脏病杂志,2018,26:621-623.
|
| [16] |
Yang J D, Addissie B D, Mara K C, et al. GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score. Cancer Epidemiol Biomarkers Prev, 2019,28:531-538.
|
